Expert Insights on Neurological Research

A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury

Study Overview The clinical trial investigated the efficacy of MLC901, also known as NeuroAiD II, in addressing cognitive deficits resulting

A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury Read Post »

Scroll to Top